ACC 2026: Baxdrostat lowers BP in uncontrolled hypertension

At the 2026 ACC Scientific Session in New Orleans, researchers presented a meta-analysis of three randomized trials (1,264 patients) evaluating baxdrostat’s blood pressure effects and safety in patients with uncontrolled hypertension on standard therapy.